List view / Grid view
In this article, Dr Raminderpal Singh speaks to Janette Thomas of Five Alarm Bio for a biotech CEO’s perspective on the complexity of data faced by both large and small biotechs. Janette is on a mission to develop drugs targeting the chronic diseases associated with ageing. She shares her insights…
So-called undruggable pharmaceutical targets could be tackled with intermediate sized drugs such as macrocycles, combining the advantages of small molecules and biologics. The preparation of very large libraries of chemically synthesised intermediate-sized molecules is now in reach with a new technology developed at ETH Zurich. In this article, Dr Michelle…
Renowned immunologist Dr Yang Liu shares his insights into the preclinical studies behind the development of drug candidates targeting the CD24/Siglec-10 pathway. He discusses the technical and regulatory hurdles of antibody development, how these therapies compare to existing immunotherapies, and the potential for personalised cancer treatment through biomarker development.
Driven by a passion for early-stage scientific discovery, Cristina de Min, MD, Chief Medical Officer at Topas Therapeutics, transitioned from clinical practice to drug development. Her expertise has played a pivotal role in advancing new treatments, with her achievements demonstrating her commitment to improving patient outcomes.
In this article, Dr Raminderpal Singh speaks to Neil Wilkie of Mironid Ltd. for a biotech CEO’s perspective on the transformative potential of AI, and the importance of bridging communication gaps between scientific and technical teams to drive innovation and efficiency in the pharmaceutical industry.
Developing cell therapies solely with healthy donor material can jeopardise clinical outcomes, introducing risks ranging from faulty preclinical data to manufacturing failures. We spoke to Priya Baraniak, CBO at OrganaBio, who advocates for early integration of diseased donor material, improved biobanking infrastructure, and cross-industry collaboration to develop more effective, patient-relevant…
Radioimmunotherapy (RIT) is a promising cancer treatment gaining recognition in precision oncology. It utilises radiolabelled antibodies to deliver targeted radiation to tumours, with success in hematologic cancers. However, its use in solid tumours has been limited by off-target radiation and toxicity, with few clinical trials advancing beyond phase II. Alexander…
The success of CAR-Ts in oncology has stoked enthusiasm for developing comparable curative therapies in other disease areas. CellProthera’s Chief Scientific Officer, Ibon Garitaonandia, explains the potential and progress for CGTs in cardiology, where disease-modifying therapies are largely non-existent.
Curiosity about the functioning of the human body and a genuine desire to benefit others drew Gilda Ascione into the world of medicine. Here, Dr Ascione, Medical Director Oncology at Daiichi Sankyo Italy, reveals the reality of being a female in STEM and why following your passion is always worthwhile.
Biolojic Design is redefining antibody therapies by creating “programmable” antibodies that intelligently target well-validated autoimmune and oncology pathways. In this Q&A, CEO and founder Yanay Ofran, PhD, describes Biolojic’s groundbreaking approach, which leverages AI and machine learning to design antibodies capable of adjusting their behaviour based on their biological environment.…
In this in-depth Q&A, Mutlu Dogruel, Vice President of AI at Cresset shares his insights surrounding chatbots, retrieval augmented generation and AI hallucinations, to open up new possibilities for innovation in pharmaceutical research.
Drug resistance is the leading cause of poor clinical outcomes for cancer patients undergoing targeted therapies. While current treatments are designed to inhibit targets along established oncogenic signalling cascades, a new, exciting approach is to address non-oncogene-related resistance mechanisms that operate in parallel to the “classic” oncogene pathways. Blocking transcriptional…
In this four-part series, Dr Raminderpal Singh discusses the challenges surrounding limited data quality and offers some pragmatic solutions. In this fourth article, he talks to John Conway, Chief Visioneer Officer at 20/15 Visioneers for an expert perspective.
In this Q&A, Dr Alan D. Roth, CEO of Oxford Drug Design, explains how his AI drug discovery company, which develops novel molecules for use in cancer treatments, has completed the first in vivo validation in its potential first-in-class approach against multiple tumours. A 28-day mouse trial showed clear efficacy…
In this Q&A, Kristina Torfgård, CEO of IRLAB Therapeutics, discusses the Company’s current drug development pipeline, including two promising preclinical projects. Kristina also details their proprietary drug discovery and development platform which has enabled the production of many first-in-class candidates, and what she envisions for the future.
